Kairos Intangible Assets from 2010 to 2026
| KAPA Stock | 0.76 0.02 2.56% |
Intangible Assets | First Reported 2010-12-31 | Previous Quarter 199.8 K | Current Value 369.6 K | Quarterly Volatility 182.3 K |
Check Kairos Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kairos Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 127.1 K, Interest Expense of 1 M or Selling General Administrative of 1.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 3.42. Kairos financial statements analysis is a perfect complement when working with Kairos Pharma Valuation or Volatility modules.
Kairos | Intangible Assets | Build AI portfolio with Kairos Stock |
Latest Kairos Pharma's Intangible Assets Growth Pattern
Below is the plot of the Intangible Assets of Kairos Pharma over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. Kairos Pharma's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kairos Pharma's overall financial position and show how it may be relating to other accounts over time.
| Intangible Assets | 10 Years Trend |
|
Intangible Assets |
| Timeline |
Kairos Intangible Assets Regression Statistics
| Arithmetic Mean | 596,435 | |
| Geometric Mean | 557,547 | |
| Coefficient Of Variation | 30.56 | |
| Mean Deviation | 149,033 | |
| Median | 702,000 | |
| Standard Deviation | 182,286 | |
| Sample Variance | 33.2B | |
| Range | 502.2K | |
| R-Value | (0.77) | |
| Mean Square Error | 14.6B | |
| R-Squared | 0.59 | |
| Significance | 0.0003 | |
| Slope | (27,683) | |
| Total Sum of Squares | 531.6B |
Kairos Intangible Assets History
About Kairos Pharma Financial Statements
Kairos Pharma stakeholders use historical fundamental indicators, such as Kairos Pharma's Intangible Assets, to determine how well the company is positioned to perform in the future. Although Kairos Pharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Kairos Pharma's assets and liabilities are reflected in the revenues and expenses on Kairos Pharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Kairos Pharma. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Intangible Assets | 199.8 K | 369.6 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kairos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kairos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kairos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kairos Pharma Stock:Check out the analysis of Kairos Pharma Correlation against competitors. For information on how to trade Kairos Stock refer to our How to Trade Kairos Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kairos Pharma. If investors know Kairos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kairos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Kairos Pharma is measured differently than its book value, which is the value of Kairos that is recorded on the company's balance sheet. Investors also form their own opinion of Kairos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Kairos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kairos Pharma's market value can be influenced by many factors that don't directly affect Kairos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kairos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kairos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kairos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.